Technical Analysis for TPTX - Turning Point Therapeutics, Inc.

Grade Last Price % Change Price Change
C 78.06 -0.69% -0.54
TPTX closed down 0.69 percent on Friday, September 17, 2021, on 1.76 times normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Strong Down Up Down
Historical TPTX trend table...

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Hammer Candlestick Bullish -0.69%
1,2,3 Pullback Bullish Bullish Swing Setup -0.69%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -0.69%
MACD Bearish Signal Line Cross Bearish 0.06%
Doji - Bullish? Reversal 0.06%
Multiple of Ten Bearish Other 0.94%
Wide Bands Range Expansion 0.94%
Doji - Bearish? Reversal -1.51%
Multiple of Ten Bearish Other -1.51%
Older End-of-Day Signals for TPTX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Possible NR7 about 23 hours ago
Down 2 % 1 day ago
2x Volume Pace 1 day ago
1.5x Volume Pace 1 day ago
Down 1% 1 day ago
View Earlier Intraday Alerts

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Turning Point Therapeutics, Inc. Description

Turning Point Therapeutics is a clinical-stage precision oncology company with a pipeline of internally discovered investigational drugs designed to address key limitations of existing cancer therapies. The company’s lead program, repotrectinib, is a next-generation kinase inhibitor targeting genetic drivers of non-small cell lung cancer and advanced solid tumors. Repotrectinib has shown antitumor activity and durable responses among kinase inhibitor treatment-naïve and pre-treated patients, and is planned to enter a registrational Phase 2 study in the second half of 2019. Turning Point’s kinase inhibitors are designed to bind to their targets with greater precision and affinity than existing therapies, with a novel, compact structure that has demonstrated an ability to potentially overcome treatment resistance common with other kinase inhibitors. The company is driven to develop therapies that mark a turning point for patients in their cancer treatment.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Solid Tumors Treatment Of Cancer Oncology Chemical Compounds Non Small Cell Lung Cancer Small Cell Lung Cancer Antineoplastic Drugs Cancer Treatment Targeted Therapy Cancer Therapies Signal Transduction Advanced Solid Tumors Protein Kinase Inhibitors Turning Kinase Pyrrolidines Entrectinib

Is TPTX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 141.23
52 Week Low 59.73
Average Volume 287,790
200-Day Moving Average 91.61
50-Day Moving Average 70.52
20-Day Moving Average 76.76
10-Day Moving Average 78.47
Average True Range 3.09
ADX 32.28
+DI 23.43
-DI 12.64
Chandelier Exit (Long, 3 ATRs) 72.93
Chandelier Exit (Short, 3 ATRs) 70.48
Upper Bollinger Bands 84.59
Lower Bollinger Band 68.94
Percent B (%b) 0.58
BandWidth 20.39
MACD Line 2.46
MACD Signal Line 2.70
MACD Histogram -0.2433
Fundamentals Value
Market Cap 3.76 Billion
Num Shares 48.2 Million
EPS -5.25
Price-to-Earnings (P/E) Ratio -14.87
Price-to-Sales 176.00
Price-to-Book 7.91
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 81.60
Resistance 3 (R3) 81.56 80.35 81.01
Resistance 2 (R2) 80.35 79.45 80.37 80.81
Resistance 1 (R1) 79.20 78.89 78.60 79.24 80.62
Pivot Point 77.99 77.99 77.68 78.01 77.99
Support 1 (S1) 76.84 77.09 76.24 76.88 75.50
Support 2 (S2) 75.63 76.53 75.65 75.31
Support 3 (S3) 74.48 75.63 75.11
Support 4 (S4) 74.52